Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

IL-17A as a potential therapeutic target for patients on peritoneal dialysis

Marchant, Vanessa, Tejera-Muñoz, Antonio, Marquez-Expósito, Laura, Rayego-Mateos, Sandra, Rodrigues-Diez, Raul R., Tejedor, Lucia, Santos-Sanchez, Laura, Egido, Jesús, Ortiz, Alberto, Valdivielso, Jose M., Fraser, Donald J. ORCID:, López-Cabrera, Manuel, Selgas, Rafael and Ruiz-Ortega, Marta 2020. IL-17A as a potential therapeutic target for patients on peritoneal dialysis. Biomolecules 10 (10) , 1361. 10.3390/biom10101361

[thumbnail of biomolecules-10-01361-v2.pdf]
PDF - Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview


Chronic kidney disease (CKD) is a health problem reaching epidemic proportions. There is no cure for CKD, and patients may progress to end-stage renal disease (ESRD). Peritoneal dialysis (PD) is a current replacement therapy option for ESRD patients until renal transplantation can be achieved. One important problem in long-term PD patients is peritoneal membrane failure. The mechanisms involved in peritoneal damage include activation of the inflammatory and immune responses, associated with submesothelial immune infiltrates, angiogenesis, loss of the mesothelial layer due to cell death and mesothelial to mesenchymal transition, and collagen accumulation in the submesothelial compact zone. These processes lead to fibrosis and loss of peritoneal membrane function. Peritoneal inflammation and membrane failure are strongly associated with additional problems in PD patients, mainly with a very high risk of cardiovascular disease. Among the inflammatory mediators involved in peritoneal damage, cytokine IL-17A has recently been proposed as a potential therapeutic target for chronic inflammatory diseases, including CKD. Although IL-17A is the hallmark cytokine of Th17 immune cells, many other cells can also produce or secrete IL-17A. In the peritoneum of PD patients, IL-17A-secreting cells comprise Th17 cells, γδ T cells, mast cells, and neutrophils. Experimental studies demonstrated that IL-17A blockade ameliorated peritoneal damage caused by exposure to PD fluids. This article provides a comprehensive review of recent advances on the role of IL-17A in peritoneal membrane injury during PD and other PD-associated complications.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Additional Information: This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license (
Publisher: MDPI
ISSN: 2218-273X
Date of First Compliant Deposit: 10 December 2020
Date of Acceptance: 22 September 2020
Last Modified: 05 May 2023 22:02

Citation Data

Cited 5 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics